BDX vs. DXCM, BSX, RMD, SYK, WST, MCK, EW, ZTS, HCA, and GSK
Should you be buying Becton, Dickinson and Company stock or one of its competitors? The main competitors of Becton, Dickinson and Company include DexCom (DXCM), Boston Scientific (BSX), ResMed (RMD), Stryker (SYK), West Pharmaceutical Services (WST), McKesson (MCK), Edwards Lifesciences (EW), Zoetis (ZTS), HCA Healthcare (HCA), and GSK (GSK). These companies are all part of the "medical" sector.
DexCom (NASDAQ:DXCM) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk.
DexCom has a net margin of 14.95% compared to DexCom's net margin of 6.44%. Becton, Dickinson and Company's return on equity of 28.31% beat DexCom's return on equity.
DexCom received 356 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 71.98% of users gave DexCom an outperform vote while only 62.25% of users gave Becton, Dickinson and Company an outperform vote.
93.9% of DexCom shares are held by institutional investors. Comparatively, 86.7% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of DexCom shares are held by company insiders. Comparatively, 0.3% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Becton, Dickinson and Company has higher revenue and earnings than DexCom. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
In the previous week, DexCom had 12 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 26 mentions for DexCom and 14 mentions for Becton, Dickinson and Company. DexCom's average media sentiment score of 0.89 beat Becton, Dickinson and Company's score of 0.62 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.
DexCom currently has a consensus target price of $136.67, indicating a potential upside of 1.44%. Becton, Dickinson and Company has a consensus target price of $279.17, indicating a potential upside of 17.44%. Given DexCom's higher possible upside, analysts plainly believe Becton, Dickinson and Company is more favorable than DexCom.
DexCom has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.
Summary
DexCom beats Becton, Dickinson and Company on 14 of the 19 factors compared between the two stocks.
Get Becton, Dickinson and Company News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Becton, Dickinson and Company Competitors List
Related Companies and Tools